|
1
|
Artene SA, Turcu-Stiolica A, Ciurea ME, Folcuti C, Tataranu LG, Alexandru O, Purcaru OS, Tache DE, Boldeanu MV, Silosi C and Dricu A: Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: A meta-analysis of published clinical trials. Sci Rep. 8(11800)2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
van Elsas MJ, van Hall T and van der Burg SH: Future challenges in cancer resistance to immunotherapy. Cancers (Basel). 12(935)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Oprita A and Sevastre AS: New pharmaceutical dosage forms used in the treatment of breast cancer. Polymeric micelles. Medico Oncol. 1:38–52. 2020.
|
|
4
|
Sevastre AS, Baloi SC, Cioc CE and Oprita A: New pharmaceutical dosage forms used in the treatment of breast cancer. Liposomes. Medico Oncol. 2:10–24. 2021.
|
|
5
|
Cosaceanu D, Carapancea M, Alexandru O, Budiu R, Martinsson HS, Starborg M, Vrabete M, Kanter L, Lewensohn R and Dricu A: Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro. Growth Factors. 25:1–8. 2007.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 17 (Suppl 4):iv1–iv62. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kleihues P and Cavenee W: Tumours of the nervous system: World Health Organization classification of tumours. IARC Press, Lyon, 2000.
|
|
8
|
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al: The somatic genomic landscape of glioblastoma. Cell. 155:462–477. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zhang J, Stevens MF and Bradshaw TD: Temozolomide: Mechanisms of action, repair and resistance. Curr Mol Pharmacol. 5:102–114. 2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J and Ram Z: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 5:79–88. 2003.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chiocca EA, Aguilar LK, Bell SD, Kaur B, Hardcastle J, Cavaliere R, McGregor J, Lo S, Ray-Chaudhuri A, Chakravarti A, et al: Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol. 29:3611–3619. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Vollmann-Zwerenz A, Leidgens V, Feliciello G, Klein CA and Hau P: Tumor cell invasion in glioblastoma. Int J Mol Sci. 21(1932)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Fernandes C, Costa A, Osório L, Lago RC, Linhares P, Carvalho B and Caeiro C: Current standards of care in glioblastoma therapy. In: Glioblastoma. De Vleeschouwer S (ed). Codon Publications, Brisbane, AU, Chapter 11, 2017.
|
|
15
|
Lee SY: Temozolomide resistance in glioblastoma multiforme. Genes Dis. 3:198–210. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Alves AL, Gomes IN, Carloni AC, Rosa MN, da Silva LS, Evangelista AF, Reis RM and Silva VA: Role of glioblastoma stem cells in cancer therapeutic resistance: A perspective on antineoplastic agents from natural sources and chemical derivatives. Stem Cell Res Ther. 12(206)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fleurence J, Bahri M, Fougeray S, Faraj S, Vermeulen S, Pinault E, Geraldo F, Oliver L, Véziers J, Marquet P, et al: Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside. Int J Cancer. 146:424–438. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Horescu C, Elena Cioc C, Tuta C, Sevastre AS, Tache DE, Alexandru O, Artene SA, Danoiu S, Dricu A and Stefana Oana P: The effect of temozolomide in combination with doxorubicin in glioblastoma cells in vitro. J Immunoassay Immunochem. 41:1033–1043. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, et al: Panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. J Clin Oncol. 32: (Suppl 15)(S2020)2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, et al: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): A randomised, open-label, phase 3 trial. Lancet. 393:678–688. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Parrozzani R, Lombardi G, Midena E, Londei D, Padovan M, Marchione G, Caccese M, Midena G, Zagonel V and Frizziero L: Ocular side effects of EGFR-inhibitor ABT-414 in recurrent glioblastoma: A long-term safety study. Front Oncol. 10(593461)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M and Choulier L: A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials. Cancers (Basel). 13(1795)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, Patel AS, Rizk EB, Suki D, Sawaya R and Glantz M: Association of the extent of resection with survival in glioblastoma: A systematic review and meta-analysis. JAMA Oncol. 2:1460–1469. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Alexandru O, Horescu C, Sevastre AS, Cioc CE, Baloi C, Oprita A and Dricu A: Receptor tyrosine kinase targeting in glioblastoma: Performance, limitations and future approaches. Contemp Oncol (Pozn). 24:55–66. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kleinberg L: Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: Patient selection and perspectives on a low-burden therapy. Patient Prefer Adherence. 10:2397–2406. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Thirupathy A, Srinivas P, Babu DS and Mamidi S: Formulation and evaluation of sustained release implantable microspheres of temozolomide for brain targeting prepared by a novel technique. Int J Pharm Pharm Sci. 3:187–194. 2011.
|
|
27
|
Lam FC, Morton SW, Wyckoff J, Vu Han TL, Hwang MK, Maffa A, Balkanska-Sinclair E, Yaffe MB, Floyd SR and Hammond PT: Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun. 9(1991)2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Fang C, Wang K, Stephen ZR, Mu Q, Kievit FM, Chiu DT, Press OW and Zhang M: Temozolomide nanoparticles for targeted glioblastoma therapy. ACS Appl Mater Interfaces. 7:6674–6682. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ramalho MJ, Sevin E, Gosselet F, Lima J, Coelho MAN, Loureiro JA and Pereira MC: Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment. Int J Pharm. 545:84–92. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Bertucci A, Prasetyanto EA, Septiadi D, Manicardi A, Brognara E, Gambari R, Corradini R and De Cola L: Combined delivery of temozolomide and anti-miR221 PNA using mesoporous silica nanoparticles induces apoptosis in resistant glioma Cells. Small. 11:5687–5695. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Irani M, Mir Mohamad Sadeghi G and Haririan I: A novel biocompatible drug delivery system of chitosan/temozolomide nanoparticles loaded PCL-PU nanofibers for sustained delivery of temozolomide. Int J Biol Macromol. 97:744–751. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Gürten B, Yenigül E, Sezer AD, Altan C and Malta S: Targeting of temozolomide using magnetic nanobeads: An in vitro study. Braz J Pharm Sci. 56:2020.
|
|
33
|
Chakravarty M, Ganguli P, Murahari M, Sarkar RR, Peters GJ and Mayur YC: Study of combinatorial drug synergy of novel acridone derivatives with temozolomide using in-silico and in-vitro methods in the treatment of drug-resistant glioma. Front Oncol. 11(625899)2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Artene SA, Tuţă C, Dragoi A, Alexandru O, Stefana Oana P, Tache DE, Dănciulescu MM, Boldeanu MV, Siloşi CA and Dricu A: Current and emerging EGFR therapies for glioblastoma. J Immunoassay Immunochem. 39:1–11. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Alexandru O, Purcaru SO, Tataranu LG, Lucan L, Castro J, Folcuţi C, Artene SA, Tuţă C and Dricu A: The influence of EGFR inactivation on the radiation response in high grade glioma. Int J Mol Sci. 19(229)2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J and Khasraw M: Anti-angiogenic therapy for high-grade glioma. Cochrane Database Syst Rev. 11(CD008218)2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Dietrich J, Wang D and Batchelor TT: Cediranib: Profile of a novel anti-angiogenic agent in patients with glioblastoma. Expert Opin Investig Drugs. 18:1549–1557. 2009.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Hyman DM, Rizvi N, Natale R, Armstrong DK, Birrer M, Recht L, Dotan E, Makker V, Kaley T, Kuruvilla D, et al: Phase I study of MEDI3617, a selective angiopoietin-2 inhibitor alone and combined with carboplatin/paclitaxel, paclitaxel, or bevacizumab for advanced solid tumors. Clin Cancer Res. 24:2749–2757. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Lin F, de Gooijer MC, Hanekamp D, Chandrasekaran G, Buil LC, Thota N, Sparidans RW, Beijnen JH, Würdinger T and van Tellingen O: PI3K-mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models. Clin Cancer Res. 23:1286–1298. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Popescu AM, Alexandru O, Brindusa C, Purcaru SO, Tache DE, Tataranu LG, Taisescu C and Dricu A: Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment. Int J Clin Exp Pathol. 8:7825–7837. 2015.PubMed/NCBI
|
|
41
|
Purcaru SO, Tache DE, Serban F, Folcuti RM, Georgescu AM, Stovicek PO, Danciulescu MM, Tataranu LG and Dricu A: Effect of VEGFR, PDGFR and PI3K/mTOR targeting in glioblastoma. Curr Health Sci J. 41:325–332. 2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Schijns VE, Pretto C, Devillers L, Pierre D, Hofman FM, Chen TC, Mespouille P, Hantos P, Glorieux P, Bota DA and Stathopoulos A: First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. Vaccine. 33:2690–2696. 2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Wahl LM and Pattenden T: Prophage provide a safe haven for adaptive exploration in temperate viruses. Genetics. 206:407–416. 2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Geletneky K, Hajda J, Angelova A, Leuchs B, Capper D, Bartsch AJ, Neumann JO, Schöning T, Hüsing J, Beelte B, et al: Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial. Mol Ther. 25(2620)2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Vatu BI, Artene SA, Staicu AG, Turcu-Stiolica A, Folcuti C, Dragoi A, Cioc C, Baloi SC, Tataranu LG, Silosi C and Dricu A: Assessment of efficacy of dendritic cell therapy and viral therapy in high grade glioma clinical trials. A meta-analytic review. J Immunoassay Immunochem. 40:70–80. 2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Satterlee AB, Dunn DE, Lo DC, Khagi S and Hingtgen S: Tumoricidal stem cell therapy enables killing in novel hybrid models of heterogeneous glioblastoma. Neuro Oncol. 21:1552–1564. 2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Ciurea ME, Georgescu AM, Purcaru SO, Artene SA, Emami GH, Boldeanu MV, Tache DE and Dricu A: Cancer stem cells: Biological functions and therapeutically targeting. Int J Mol Sci. 15:8169–8185. 2014.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455:1061–1068. 2008.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Liu S, Tang Y, Yuan X, Yuan D, Liu J, Li B and Li Y: Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells. Invest New Drugs. 36:961–969. 2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Forte IM, Indovina P, Iannuzzi CA, Cirillo D, Di Marzo D, Barone D, Capone F, Pentimalli F and Giordano A: Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. Int J Oncol. 54:2189–2199. 2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, et al: A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol. 126:185–192. 2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Piao Y, Park SY, Henry V, Smith BD, Tiao N, Flynn DL and de Groot JF: Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro Oncol. 18:1230–1241. 2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Payton M, Jun T, Wayne W, Yu D, Manoukian R, Chung G, Zhang N, Sun JR, Kaplan-Lefko P, Scully S, et al: Antagonism of Ang-Tie2 and Dll4-Notch signaling has opposing effects on tumor endothelial cell proliferation, evidenced by a new flow cytometry method. Lab Invest. 94:1296–1308. 2014.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, et al: Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 28:1168–1174. 2010.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Wen PY, Cloughesy TF, Olivero AG, Morrissey KM, Wilson TR, Lu X, Mueller LU, Coimbra AF, Ellingson BM, Gerstner E, et al: First-in-human phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma. Clin Cancer Res. 26:1820–1828. 2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Maklad A, Sharma A and Azimi I: Calcium signaling in brain cancers: Roles and therapeutic targeting. Cancers (Basel). 11(145)2019.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E and Adolf GR: Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 343:342–350. 2012.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Dermawan JK, Hitomi M, Silver DJ, Wu Q, Sandlesh P, Sloan AE, Purmal AA, Gurova KV, Rich JN, Lathia JD, et al: Pharmacological targeting of the histone chaperone complex FACT preferentially eliminates glioblastoma stem cells and prolongs survival in preclinical models. Cancer Res. 76:2432–2442. 2016.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Stylli SS: Novel treatment strategies for glioblastoma. Cancers (Basel). 12(2883)2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Bloch O, Lim M, Sughrue ME, Komotar RJ, Abrahams JM, O'Rourke DM, D'Ambrosio A, Bruce JN and Parsa AT: Autologous heat shock protein peptide vaccination for newly diagnosed glioblastoma: impact of peripheral PD-L1 expression on response to therapy. Clin Cancer Res. 23:3575–3584. 2017.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Krendyukov A and Gieffers C: Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies. Cancer Manag Res. 11:8095–8100. 2019.PubMed/NCBI View Article : Google Scholar
|
|
62
|
von Achenbach C, Silginer M, Blot V, Weiss WA and Weller M: Depatuxizumab mafodotin (ABT-414)-induced glioblastoma cell death requires EGFR overexpression, but not EGFRY1068 phosphorylation. Mol Cancer Ther. 19:1328–1339. 2020.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Lukas RV, Juhász C, Wainwright DA, James CD, Kennedy E, Stupp R and Lesniak MS: Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod. J Neurooncol. 141:111–120. 2019.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Angelova AL, Barf M, Geletneky K, Unterberg A and Rommelaere J: Immunotherapeutic potential of oncolytic H-1 parvovirus: Hints of glioblastoma microenvironment conversion towards immunogenicity. Viruses. 15(382)2017.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Alphandéry E: Glioblastoma treatments: An account of recent industrial developments. Front Pharmacol. 9(879)2018.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Łata S and Molczyk A: Side effects of temozolomide treatment in patient with glioblastoma multiforme-case study. Przegl Lek. 67:445–446. 2010.PubMed/NCBI(In Polish).
|
|
67
|
Sabel M and Giese A: Safety profile of carmustine wafers in malignant glioma: A review of controlled trials and a decade of clinical experience. Curr Med Res Opin. 24:3239–3257. 2008.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, et al: Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 377:1954–1963. 2017.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, et al: Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro Oncol. 19:845–852. 2017.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Alshami J, Guiot MC, Owen S, Kavan P, Gibson N, Solca F, Cseh A, Reardon DA and Muanza T: Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report. Oncotarget. 6:34030–34037. 2015.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Clinical Trials: National Library of Medicine: Safety Study of VAL-083 in patients with recurrent malignant glioma. Available from: https://clinicaltrials.gov/ct2/show/NCT01478178. Accessed August 5, 2021.
|
|
72
|
Mamo A, Baig A, Azam M, Rho YS, Sahebjam S, Muanza T, Owen S, Petrecca K, Guiot MC, Al-Shami J, et al: Progression pattern and adverse events with bevacizumab in glioblastoma. Curr Oncol. 23:e468–e471. 2016.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Odia Y, Sul J, Shih JH, Kreisl TN, Butman JA, Iwamoto FM and Fine HA: A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma. CNS Oncol. 5:59–67. 2016.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Swartz AM, Li QJ and Sampson JH: Rindopepimut: A promising immunotherapeutic for the treatment of glioblastoma multiforme. Immunotherapy. 6:679–690. 2014.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Fenstermaker RA, Ciesielski MJ, Qiu J, Yang N, Frank CL, Lee KP, Mechtler LR, Belal A, Ahluwalia MS and Hutson AD: Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol Immunother. 65:1339–1352. 2016.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Rampling R, Peoples S, Mulholland PJ, James A, Al-Salihi O, Twelves CJ, McBain C, Jefferies S, Jackson A, Stewart W, et al: A cancer research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clin Cancer Res. 22:4776–4785. 2016.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, et al: A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clin Cancer Res. 25:5799–5807. 2019.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, et al: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 16(142)2018.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, et al: Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5(e8)2008.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Whittle JR, Lickliter JD, Gan HK, Scott AM, Simes J, Solomon BJ, MacDiarmid JA, Brahmbhatt H and Rosenthal MA: First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. J Clin Neurosci. 22:1889–1894. 2015.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Philbrick BD and Adamson DC: Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma. Expert Opin Investig Drugs. 28:207–216. 2019.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Chiocca EA, Yu J, Lukas RV, Buck J, Demars N, Barrett J, Yang Y, Cooper L and Lebel F: ATIM-26. A phase 1 study of AD-RTS-HIL-12 + veledimex in adult recurrent glioblastoma. Neuro Oncol. 19 (Suppl 6)(vi32)2017.
|
|
83
|
Zuccarini M, Giuliani P, Ziberi S, Carluccio M, Iorio PD, Caciagli F and Ciccarelli R: The role of Wnt signal in glioblastoma development and progression: A possible new pharmacological target for the therapy of this tumor. Genes (Basel). 9(105)2018.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Peñaranda-Fajardo NM, Meijer C, Liang Y, Dijkstra BM, Aguirre-Gamboa R, den Dunnen WFA and Kruyt FAE: ER stress and UPR activation in glioblastoma: Identification of a noncanonical PERK mechanism regulating GBM stem cells through SOX2 modulation. Cell Death Dis. 10(690)2019.PubMed/NCBI View Article : Google Scholar
|
|
85
|
European Medicines Agency: COVID-19 pandemic. Available from: www.ema.europa.eu. Accessed September 5, 2021.
|
|
86
|
Günther W, Pawlak E, Damasceno R, Arnold H and Terzis AJ: Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. Br J Cancer. 88:463–469. 2003.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Darlix A, Baumann C, Lorgis V, Ghiringhelli F, Blonski M, Chauffert B, Zouaoui S, Pinelli C, Rech F, Beauchesne P and Taillandier L: Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. Anticancer Res. 33:3467–3474. 2013.PubMed/NCBI
|
|
88
|
Nonnenmacher L, Westhoff MA, Fulda S, Karpel-Massler G, Halatsch ME, Engelke J, Simmet T, Corbacioglu S and Debatin KM: RIST: A potent new combination therapy for glioblastoma. Int J Cancer. 136:E173–E187. 2015.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Halatsch ME, Kast RE, Dwucet A, Hlavac M, Heiland T, Westhoff MA, Debatin KM, Wirtz CR, Siegelin MD and Karpel-Massler G: Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma. Br J Pharmacol. 176:3681–3694. 2019.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Affronti ML, Heery CR, Herndon JE II, Rich JN, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Bigner DD and Friedman HS: Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 115:3501–3511. 2009.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Clinical Trials: National Library of Medicine: O6-benzylguanine-mediated tumor sensitization with chemoprotected autologous stem cell in treating patients with malignant gliomas. Available from: https://clinicaltrials.gov/ct2/show/NCT00669669?term=carmustine&recrs=d&cond=glioblastoma&draw=2&rank=1. Accessed February 25, 2021.
|
|
92
|
National Library of Medicine: National Center for Biotechnology Information: Lomustine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Lomustine. Accessed February 25, 2021.
|
|
93
|
Reimunde P, Pensado-López A, Carreira Crende M, Lombao Iglesias V, Sánchez L, Torrecilla-Parra M, Ramírez CM, Anfray C and Torres Andón F: Cellular and molecular mechanisms underlying glioblastoma and zebrafish models for the discovery of new treatments. Cancers (Basel). 13(1087)2021.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, Mathieu D, Phuphanich S, Cseh A, Fu Y, et al: Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 17:430–439. 2015.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Vengoji R, Macha MA, Nimmakayala RK, Rachagani S, Siddiqui JA, Mallya K, Gorantla S, Jain M, Ponnusamy MP, Batra SK and Shonka N: Afatinib and temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. J ExpClin Cancer Res. 38(266)2019.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Oprita A, Baloi SC, Staicu GA, Alexandru O, Tache DE, Danoiu S, Micu ES and Sevastre AS: Updated insights on EGFR signaling pathways in glioma. Int J Mol Sci. 22(587)2021.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Clinical Trials: National Library of Medicine. Available from: https://clinicaltrials.gov/. Accessed April 5, 2021.
|
|
98
|
Lassman AB, Pugh SL, Gilbert MR, Aldape KD, Geinoz S, Beumer JH, Christner SM, Komaki R, DeAngelis LM, Gaur R, et al: Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol. 17:992–998. 2015.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M, Lolli I, Pace A, Daniele B, Pasqualetti F, et al: Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): A multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 20:110–119. 2019.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Stehman FB, Blom J, Blessing JA, Ehrlich CE and Mangan C: Phase II trial of galactitol 1,2:5,6-dianhydro (NSC 132313) in the treatment of advanced gynecologic malignancies: A gynecologic oncology group study. Gynecol Oncol. 15:381–390. 1983.PubMed/NCBI View Article : Google Scholar
|
|
101
|
O'Brien B, Groot J, Kamiya-Matsuoka C, Weathers SP, Bacha J, Brown D, Steino A, Langlands J, Schwartz R, Kanekal S, et al: ACTR-27. Phase 2 study of dianhydrogalactitol (val-083) in patients with MGMT-unmethylated, bevacizumab-naïve recurrent glioblastoma. Neuro Oncol. 20 (Suppl 6)(vi17)2018.
|
|
102
|
Keir ST, Friedman HS, Reardon DA, Bigner DD and Gray LA: Mibefradil, a novel therapy for glioblastoma multiforme: Cell cycle synchronization and interlaced therapy in a murine model. J Neurooncol. 111:97–102. 2013.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Lester-Coll NH, Supko JG, Kluytenaar J, Pavlik KF, Yu JB, Moliterno J, Piepmeier J, Becker K, Baehring JM, Huttner A, et al: Mibefradil dihydrochoride with hypofractionated radiation for recurrent glioblastoma: A phase I dose expansion trial. J Clin Oncol. 36 (Suppl 15)(e14046)2018.
|
|
104
|
Clinical Trials: National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/results?cond=glioblastoma&term=mibefradil&cntry=&state=&city=&dist=. Accessed February 20, 2021.
|
|
105
|
Wang N, Jain RK and Batchelor TT: New Directions in anti-angiogenic therapy for glioblastoma. Neurotherapeutics. 14:321–332. 2017.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Arbab AS: Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma. Histol Histopathol. 27:549–557. 2012.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Lu G, Rao M, Zhu P, Liang B, El-Nazer RT, Fonkem E, Bhattacharjee MB and Zhu JJ: Triple-drug therapy with bevacizumab, irinotecan, and temozolomide plus tumor treating fields for recurrent glioblastoma: A retrospective study. Front Neurol. 10(42)2019.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, et al: A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/north central cancer treatment group N0872. Cancer. 125:3790–3800. 2019.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Akiyode O and Dunkelly-Allen N: Ranibizumab: A review of its use in the treatment of diabetic retinopathy in patients with diabetic macular edema. J Pharm Technol. 32:22–28. 2016.
|
|
111
|
Batchelor TT, Gerstner ER, Ye X, Desideri S, Duda DG, Peereboom D, Lesser GJ, Chowdhary S, Wen PY, Grossman S and Supko JG: Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro Oncol. 19:567–575. 2017.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, et al: Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 31:3212–3218. 2013.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, et al: Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA. 110:19059–19064. 2013.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Odia Y, Iwamoto FM, Moustakas A, Fraum TJ, Salgado SA, Li A, Kreisl TN, Sul J, Butman JA and Fine HA: A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas. J Neuro Oncol. 127:127–135. 2016.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Clinical Trials: A Trial of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma with or without the novel genomic biomarker, DGM1. Available from: https://clinicaltrials.gov/ct2/show/NCT03776071. Accessed January 15, 2021.
|
|
116
|
Limeta A, Ji B, Levin M, Gatto F and Nielsen J: Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma. JCI Insight. 5(e140940)2020.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD and Goldhirsch A: Cancer immunotherapy efficacy and patients' sex: A systematic review and meta-analysis. Lancet Oncol. 19:737–746. 2018.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Tarantino P, Gandini S, Trapani D, Criscitiello C and Curigliano G: Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 159(103223)2021.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Reardon DA, Omuro A, Brandes AA, Rieger J, Wick A, Sepulveda J, Phuphanich S, de Souza P, Ahluwalia MS, Lim M, et al: Os10.3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: Checkmate 143. Neuro Oncol. 19 (Suppl 3)(iii21)2017.
|
|
120
|
Clinical Trials: National Library of Medicine: Available from: https://clinicaltrials.gov/ct2/results?cond=Glioblastoma&term=immunotherapy&cntry=&state=&city=&dist=. Accessed September 3, 2021.
|
|
121
|
Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, Lebbe C, Belin C, Ursu R and Carpentier AF: Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. Eur J Cancer. 73:1–8. 2017.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, et al: Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial. Lancet Oncol. 18:1373–1385. 2017.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, et al: A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 17:854–861. 2015.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Wood CG and Mulders P: Vitespen: A preclinical and clinical review. Future Oncol. 5:763–774. 2009.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Clinical Trials: Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence. Available from: https://clinicaltrials.gov/ct2/show/NCT04013672?term=SurVaxM&cond=glioblastoma&draw=2&rank=1. Accessed April 5, 2021.
|
|
126
|
Migliorini D and Dutoit V: ATIM-21. IMA950 peptide-based vaccine adjuvanted with poly-ICLC in combination with standard therapy in newly diagnosed HLA-A2 glioblastoma patients: Preliminary results. Neuro Oncol. 18 (Suppl 6)(vi22)2016.
|
|
127
|
Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, Kubota T and Yang WK: A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci. 18:1048–1054. 2011.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuño MA, Richardson JE, Fan X, Ji J, Chu RM, et al: Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 62:125–135. 2013.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Wick W and van den Bent MJ: First results on the DCVax phase III trial: Raising more questions than providing answers. Neuro Oncol. 20:1283–1284. 2018.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Polyzoidis S and Ashkan K: DCVax®-L-developed by Northwest Biotherapeutics. Hum Vaccin Immunother. 10:3139–3145. 2014.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Van Gool SW, Makalowski J, Fiore S, Sprenger T, Prix L, Schirrmacher V and Stuecker W: Randomized controlled immunotherapy clinical trials for GBM challenged. Cancers (Basel). 13(32)2020.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Wick W, Fricke H, Junge K, Kobyakov G, Martens T, Heese O, Wiestler B, Schliesser MG, von Deimling A, Pichler J, et al: A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. Clin Cancer Res. 20:6304–6313. 2014.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Wick W, Krendyukov A, Junge K, Höger T and Fricke H: Longitudinal analysis of quality of life following treatment with asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients. J Neurooncol. 145:531–540. 2019.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, et al: Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: Results from an international phase I multicenter trial. Neuro Oncol. 21:106–114. 2019.PubMed/NCBI View Article : Google Scholar
|
|
135
|
van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, et al: Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: Results from a multi-center, international study. Cancer Chemother Pharmacol. 80:1209–1217. 2017.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Phuphanich S, Raizer J, Chamberlain M, Canelos P, Narwal R, Hong S, Miday R, Nade M and Laubscher K: Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma. J Neurooncol. 131:185–191. 2017.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Caster JM, Patel AN, Zhang T and Wang A: Investigational nanomedicines in 2016: A review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 9:2017.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Mozhei O, G Teschemacher A and Kasparov S: Viral vectors as gene therapy agents for treatment of glioblastoma. Cancers (Basel). 12(3724)2020.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Banerjee K, Núñez FJ, Haase S, McClellan BL, Faisal SM, Carney SV, Yu J, Alghamri MS, Asad AS, Candia AJN, et al: Current approaches for glioma gene therapy and virotherapy. Front Mol Neurosci. 14(621831)2021.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Caffery B, Lee JS and Alexander-Bryant AA: Vectors for glioblastoma gene therapy: Viral & non-viral delivery strategies. Nanomaterials (Basel). 9(105)2019.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Rubsam LZ, Boucher PD, Murphy PJ, KuKuruga M and Shewach DS: Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Cancer Res. 59:669–675. 1999.PubMed/NCBI
|
|
142
|
Clinical Trials: Gene Therapy for the Treatment of Brain Tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT00001328. Accessed January 20, 2021.
|
|
143
|
Ji N, Weng D, Liu C, Gu Z, Chen S, Guo Y, Fan Z, Wang X, Chen J, Zhao Y, et al: Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma. Oncotarget. 7:4369–4378. 2016.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Clinical Trials: HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM. Available from: https://clinicaltrials.gov/ct2/show/NCT03603405.
|
|
145
|
Zadeh G, Bota D, Cachia D, Landolfi J, Schiff D, Vogelbaum MA, Walbert T, Tran D, Chu A, Das A, et al: PC3-151 Toca 5: A phase 2/3 randomized, open-label study of Toca 511, a retroviral replicating vector, combined with Toca FC versus standard of care in patients undergoing planned resection for recurrent glioblastoma (GBM) or anaplastic astrocytoma (AA) (NCT02414165). Can J NeurolSci. 43 (Suppl 4)(S17)2016.
|
|
146
|
Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, et al: Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med. 8(341ra75)2016.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Chiocca EA, Yu JS, Lukas RV, Solomon IH, Ligon KL, Nakashima H, Triggs DA, Reardon DA, Wen P, Stopa BM, et al: Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med. 11(eaaw5680)2019.PubMed/NCBI View Article : Google Scholar
|
|
148
|
Clinical Trials: Study of Ad-RTS-hIL-12 + veledimex in combination with cemiplimab in subjects with recurrent or progressive glioblastoma. Available from: https://clinicaltrials.gov/ct2/show/NCT04006119. Accessed February 3, 2021.
|
|
149
|
Kim SS, Rait A, Kim E, Pirollo KF and Chang EH: A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Nanomedicine. 11:301–311. 2015.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Clinical Trials: Phase II study of combined temozolomide and SGT-53 for treatment of recurrent glioblastoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02340156. Accessed February 3, 2021.
|
|
151
|
Kumthekar P, Rademaker A, Ko C, Dixit K, Schwartz MA, Sonabend AM, Sharp L, Vincas Lukas R, Stupp R, Horbinski C, et al: A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients. J Clin Oncol. 37 (Suppl 15)(S3012)2019.
|
|
152
|
Lacroix J, Leuchs B, Li J, Hristov G, Deubzer HE, Kulozik AE, Rommelaere J, Schlehofer JR and Witt O: Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells. Int J Cancer. 127:1230–1239. 2010.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Sevastre AS, Horescu C, Baloi CS, Cioc CE, Vatu BI, Tuta C, Artene SA, Danciulescu MM, Tudorache S and Dricu A: Benefits of nanomedicine for therapeutic intervention in malignant diseases. Coatings. 9(628)2019.
|
|
154
|
Carapancea M, Alexandru O, Fetea AS, Dragutescu L, Castro J, Georgescu A, Popa-Wagner A, Bäcklund ML, Lewensohn R and Dricu A: Growth factor receptors signaling in glioblastoma cells: Therapeutic implications. J Neurooncol. 92:137–147. 2009.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Alexandru O, Dragutescu L, Tataranu L, Ciubotaru V, Sevastre A, Georgescu AM, Purcaru O, Danoiu S, Bäcklund LM and Dricu A: Helianthin induces antiproliferative effect on human glioblastoma cells in vitro. J Neurooncol. 102:9–18. 2011.PubMed/NCBI View Article : Google Scholar
|
|
156
|
Alexandru O, Sevastre AS, Castro J, Artene SA, Tache DE, Purcaru OS, Sfredel V, Tataranu LG and Dricu A: Platelet-derived growth factor receptor and ionizing radiation in high grade glioma cell lines. Int J Mol Sci. 20(4663)2019.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Sevastre AS, Buzatu IM, Baloi C, Oprita A, Dragoi A, Tataranu LG, Alexandru O, Tudorache S and Dricu A: ELTD1-an emerging silent actor in cancer drama play. Int J Mol Sci. 22(5151)2021.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Weyerhäuser P, Kantelhardt SR and Kim EL: Re-purposing chloroquine for glioblastoma: Potential merits and confounding variables. Front Oncol. 8(335)2018.PubMed/NCBI View Article : Google Scholar
|
|
159
|
Mazurek M, Litak J, Kamieniak P, Kulesza B, Jonak K, Baj J and Grochowski C: Metformin as potential therapy for high-grade glioma. Cancers (Basel). 12(210)2020.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Karamanakos PN, Trafalis DT, Papachristou DJ, Panteli ES, Papavasilopoulou M, Karatzas A, Kardamakis D, Nasioulas G and Marselos M: Evidence for the efficacy of disulfiram and copper combination in glioblastoma multiforme-A propos of a case. J BUON. 22:1227–1232. 2017.PubMed/NCBI
|
|
161
|
Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, et al: Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 12:1300–1310. 2010.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, et al: Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American brain tumor consortium trial 04-02. Neuro Oncol. 16:567–578. 2014.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Clinical Trials: Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01051557. Accessed August 1, 2021.
|
|
164
|
Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE II, Marcello J, Norfleet JA, McLendon RE, Sampson JH and Friedman HS: Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol. 96:219–230. 2010.PubMed/NCBI View Article : Google Scholar
|
|
165
|
Chheda MG, Wen PY, Hochberg FH, Chi AS, Drappatz J, Eichler AF, Yang D, Beroukhim R, Norden AD, Gerstner ER, et al: Vandetanib plus sirolimus in adults with recurrent glioblastoma: Results of a phase I and dose expansion cohort study. J Neurooncol. 121:627–634. 2015.PubMed/NCBI View Article : Google Scholar
|
|
166
|
Peereboom DM, Ahluwalia MS, Ye X, Supko JG, Hilderbrand SL, Phuphanich S, Nabors LB, Rosenfeld MR, Mikkelsen T and Grossman SA: New Approaches to Brain Tumor Therapy Consortium. NABTT 0502: A phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol. 15:490–496. 2013.PubMed/NCBI View Article : Google Scholar
|
|
167
|
Sousa F, Moura RP, Moreira E, Martins C and Sarmento B: Therapeutic monoclonal antibodies delivery for the glioblastoma treatment. Adv Protein Chem Struct Biol. 112:61–80. 2018.PubMed/NCBI View Article : Google Scholar
|
|
168
|
Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC, et al: Genome-scale CRISPR-mediated control of gene repression and activation. Cell. 159:647–661. 2014.PubMed/NCBI View Article : Google Scholar
|
|
169
|
Rosenthal M, Curry R, Reardon DA, Rasmussen E, Upreti VV, Damore MA, Henary HA, Hill JS and Cloughesy T: Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. Cancer Chemother Pharmacol. 84:327–336. 2019.PubMed/NCBI View Article : Google Scholar
|
|
170
|
Damore MA, Coberly SK, Wakamiya K, Webster S, Tanna V, Xu X, Klement I, Welcher R, Kiaei P, Liu Y, et al: An EGFRvIII-specific IHC IUO test for patient selection in AMG 595 phase I trial. J Clin Oncol. 31 (Suppl 15)(S2071)2013.
|
|
171
|
Hamblett KJ, Kozlosky CJ, Siu S, Chang WS, Liu H, Foltz IN, Trueblood ES, Meininger D, Arora T, Twomey B, et al: AMG 595, an anti-EGFRvIII antibody-drug conjugate, induces potent antitumor activity against EGFRvIII-expressing glioblastoma. Mol Cancer Ther. 14:1614–1624. 2015.PubMed/NCBI View Article : Google Scholar
|
|
172
|
Diaz-Miqueli A, Blanco R, Lemm M, Fichtner I, León K and Montero E: Preclinical efficacy of nimotuzumab, an anti-EGFR monoclonal antibody as a single agent therapy in human GBM U87MG xenografts. J Cancer Ther. 3:245–255. 2012.
|
|
173
|
Solomón MT, Selva JC, Figueredo J, Vaquer J, Toledo C, Quintanal N, Salva S, Domíngez R, Alert J, Marinello JJ, et al: Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: Results from a randomized, double blind trial. BMC Cancer. 13(299)2013.PubMed/NCBI View Article : Google Scholar
|
|
174
|
Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz D, Simon M, Schlegel U, Senft C, et al: A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer. 51:522–532. 2015.PubMed/NCBI View Article : Google Scholar
|
|
175
|
Reilly EB, Phillips AC, Buchanan FG, Kingsbury G, Zhang Y, Meulbroek JA, Cole TB, DeVries PJ, Falls HD, Beam C, et al: Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody. Mol Cancer Ther. 14:1141–1151. 2015.PubMed/NCBI View Article : Google Scholar
|
|
176
|
Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, Lwin Z, Wheeler H, Fichtel L, Scott AM, et al: Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro Oncol. 20:838–847. 2018.PubMed/NCBI View Article : Google Scholar
|
|
177
|
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004.PubMed/NCBI View Article : Google Scholar
|
|
178
|
Chadwick M, Huselid E, Bartucci M, Patrizii M, Jara K, Mehta M, Gilleran J, Augeri D and Sabaawy H: Abstract 3073: Development of novel BMI1 inhibitors targeting glioblastoma stem-like cells abstract. Cancer Res. 79 (Suppl 13)(S3073)2019.
|
|
179
|
Affinito A, Quintavalle C, Esposito CL, Roscigno G, Vilardo C, Nuzzo S, Vitiani LR, De Luca G, Minic Z, Giannetti S, et al: 1998P-The discovery of RNA-aptamers that selectively bind and inhibit glioblastoma stem cells by targeting EphA2. Ann Oncol. 30(v802)2019.PubMed/NCBI View Article : Google Scholar
|
|
180
|
Kouri FM, Ritner C and Stegh AH: miRNA-182 and the regulation of the glioblastoma phenotype-toward miRNA-based precision therapeutics. Cell Cycle. 14:3794–3800. 2015.PubMed/NCBI View Article : Google Scholar
|
|
181
|
Johnston MJ, Nikolic A, Ninkovic N, Guilhamon P, Cavalli FMG, Seaman S, Zemp FJ, Lee J, Abdelkareem A, Ellestad K, et al: High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma. Genome Res. 29:1211–1222. 2019.PubMed/NCBI View Article : Google Scholar
|
|
182
|
Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R, Ghandour G, Perkins N, Winchester E, Spencer J, et al: Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science. 280:1077–1082. 1998.PubMed/NCBI View Article : Google Scholar
|
|
183
|
Fisher JP and Adamson DC: Current FDA-approved therapies for high-grade malignant gliomas. Biomedicines. 9(324)2021.PubMed/NCBI View Article : Google Scholar
|
|
184
|
Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, et al: Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA. 104:10152–10157. 2007.PubMed/NCBI View Article : Google Scholar
|
|
185
|
Frenster JD, Desai S and Placantonakis DG: In vitro evidence for glioblastoma cell death in temperatures found in the penumbra of laser-ablated tumors. Int J Hyperthermia. 37:20–26. 2020.PubMed/NCBI View Article : Google Scholar
|
|
186
|
Rennert RC, Khan U, Bartek J, Tatter SB, Field M, Toyota B, Fecci PE, Judy K, Mohammadi AM, Landazuri P, et al: Laser ablation of abnormal neurological tissue using robotic neuroblate system (LAANTERN): Procedural safety and hospitalization. Neurosurgery. 86:538–547. 2020.PubMed/NCBI View Article : Google Scholar
|
|
187
|
Branter J, Basu S and Smith S: Tumour treating fields in a combinational therapeutic approach. Oncotarget. 9:36631–36644. 2018.PubMed/NCBI View Article : Google Scholar
|
|
188
|
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 380:358–365. 2012.PubMed/NCBI View Article : Google Scholar
|
|
189
|
Peterson YK and Luttrell LM: The diverse roles of arrestin scaffolds in G protein-coupled receptor signaling. Pharmacol Rev. 69:256–297. 2017.PubMed/NCBI View Article : Google Scholar
|
|
190
|
DeWire SM, Kim J, Whalen EJ, Ahn S, Chen M and Lefkowitz RJ: Beta-arrestin-mediated signaling regulates protein synthesis. J Biol Chem. 283:10611–10620. 2008.PubMed/NCBI View Article : Google Scholar
|
|
191
|
Artene SA, Folcuti C and Dricu A: β-arrestin 1 overexpression increases temozolomide resistance in human malignant glioma cells. Curr Health Sci J. 43:112–119. 2017.PubMed/NCBI View Article : Google Scholar
|
|
192
|
Horescu C and Artene SA: The effect of beta-arrestin 1 transfection on proliferation and temozolomide treatment response in HGG cells. Medico Oncol. 1:1–9. 2020.PubMed/NCBI View Article : Google Scholar
|
|
193
|
Blomquist MR, Ensign SF, D'Angelo F, Phillips JJ, Ceccarelli M, Peng S, Halperin RF, Caruso FP, Garofano L, Byron SA, et al: Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progression. Neurooncol Adv. 2(vdaa078)2020.PubMed/NCBI View Article : Google Scholar
|
|
194
|
White K, Connor K, Clerkin J, Murphy BM, Salvucci M, O'Farrell AC, Rehm M, O'Brien D, Prehn JHM, Niclou SP, et al: New hints towards a precision medicine strategy for IDH wild-type glioblastoma. Ann Oncol. 31:1679–1692. 2020.PubMed/NCBI View Article : Google Scholar
|
|
195
|
Liu L, Wang G, Wang L, Yu C, Li M, Song S, Hao L, Ma L and Zhang Z: Computational identification and characterization of glioma candidate biomarkers through multi-omics integrative profiling. Biol Direct. 15(10)2020.PubMed/NCBI View Article : Google Scholar
|
|
196
|
Duan R, Gao L, Gao Y, Hu Y, Xu H, Huang M, Song K, Wang H, Dong Y, Jiang C, et al: Evaluation and comparison of multi-omics data integration methods for cancer subtyping. PLoS Comput Biol. 17(e1009224)2021.PubMed/NCBI View Article : Google Scholar
|
|
197
|
Popescu SO, Costachi A, Cioc CE, Buteica A and Dricu A: Iron oxide magnetic nanoparticles as drug delivery systems for brain cancer treatment. Medico Oncol. 2:55–66. 2021.
|
|
198
|
Saenz-Antoñanzas A, Auzmendi-Iriarte J, Carrasco-Garcia E, Moreno-Cugnon L, Ruiz I, Villanua J, Egaña L, Otaegui D, Samprón N and Matheu A: Liquid biopsy in glioblastoma: Opportunities, applications and challenges. Cancers (Basel). 11(950)2019.PubMed/NCBI View Article : Google Scholar
|
